Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Merck's Frespaciguat?
Frespaciguat is a small molecule commercialized by Merck, with a leading Phase III program in Idiopathic Pulmonary Hypertension. According to...
Frespaciguat by Merck for Pulmonary Hypertension: Likelihood of Approval
Frespaciguat is under clinical development by Merck and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II...
Frespaciguat by Merck for Idiopathic Pulmonary Hypertension: Likelihood of Approval
Frespaciguat is under clinical development by Merck and currently in Phase III for Idiopathic Pulmonary Hypertension. According to GlobalData, Phase...